Pyxis Oncology(PYXS)
BOSTON, MABiotechnology
Focus: Pyxis Oncology is a public-stage biotechnology company focused on antibody immunotherapy for oncology, operating from Boston with a highly R&D-intensive business model. The company is advancing a pipeline of early-stage solid tumor and CNS cancer programs with limited commercial revenue.
Profile data last refreshed 4h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at Pyxis Oncology?
AI assessmentPyxis is a high-risk, high-upside early-stage biotech suitable only for mission-driven scientists comfortable with execution risk and limited near-term advancement opportunities.
Why Work Here
- Recent $282.6M public offering (Oct 2026) signals strong financing runway for Phase 3 advancement, reducing near-term cash crisis risk.
- Focused pipeline in high-value oncology space with antibody-based modalities (APX005M, PYX-201, PYX-106) addressing melanoma, glioblastoma, and solid tumors.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$16M
Pipeline & Clinical Trials
PYX-201
Solid TumorClinical Trials (1)
NCT05720117A Study of PYX-201 in Advanced Solid Tumors
Phase 1Help build intelligence for Pyxis Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.